Communiqués Tenax Therapeutics, Inc.

Actions

TENX

US88032L6056

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
1,850 ^USD	+2,21 %		-1,60 %	-84,82 %

31/08	Tenax Therapeutics, Inc. : Guggenheim moins optimiste	ZM
29/08	Tenax Therapeutics présente des résultats complémentaires de l'essai clinique de phase 3 évaluant le TNX-103 chez des patients atteints d'hypertension pulmonaire due à une insuffisance cardiaque à fraction d'éjection préservée	CI

Communiqués

01/09	Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference	AQ
29/08	Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026	AQ
10/08	Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF	AQ
31/07	Tenax Therapeutics: Q2 Earnings Snapshot	AQ
31/07	Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
02/07	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
02/07	Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026	AQ
12/05	Tenax Therapeutics: Q1 Earnings Snapshot	AQ
12/05	Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
08/05	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/05	Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer	AQ
22/04	Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer	AQ
10/03	Tenax Therapeutics: Q4 Earnings Snapshot	AQ
10/03	Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
03/03	Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference	AQ
04/02	Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026	AQ
18/12	Tenax Therapeutics : Announces Result of Prespecified Blinded Sample Size Assessment	PU
17/12	Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment	AQ
25/11	Tenax Therapeutics to Participate in Upcoming Investor Conferences	AQ
14/11	Tenax Therapeutics : Virtual KOL Call (cde979)	PU
12/11	Tenax Therapeutics: Q3 Earnings Snapshot	AQ
12/11	Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
06/11	Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF	AQ
03/11	Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference	AQ
16/09/25	Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF	AQ